Minimum inhibitory concentrations.

<p>Minimum inhibitory concentrations for oxytetracycline (OTC), danofloxacin (DANO) and tulathromycin (TUL) against <i>Mmm</i>SC strain B237 in artificial medium using microdilution and macrodilution techniques (inoculum size 10⁷ cfu/mL). Values were based on either just one set of doubling dilutions (micro, macro) or five overlapping sets of doubling dilutions (micro overlapping, macro overlapping).</p

Pharmacodynamic analysis of data obtained from <i>in vitro</i> time-kill studies in artificial medium and adult bovine serum for oxytetracycline (OTC), danofloxacin (DANO) and tulathromycin (TUL) against <i>Mmm</i>SC strain B237.

<p>E₀ is the difference in log₁₀ (cfu/mL) units after 24 hours compared to the initial titre when no antimicrobial is present, E_max is the maximum antimycoplasmal effect in log₁₀ (cfu/mL) units, EC₅₀ is the twenty-four hour-area under curve:minimum inhibitory concentration ratio (AUC:MIC) of antimicrobial that gives rise to 50% of the maximum response and N is the Hill coefficient. AUC:MIC ratios are provided for mycoplasmastatic activity (MS) and, where appropriate, mycoplasmacidal activity (MC) and virtual mycoplasmal elimination (VME).</p

Sigmoid E_max models.

<p>Sigmoid E_max relationships for antimycoplasmal effect (E, log₁₀ (cfu/mL)) versus <i>in vitro</i> AUC:MIC ratio, derived from data obtained from time-kill curves for (A) danofloxacin (B) oxytetracycline and (C) tulathromycin in artificial medium, and (D) danofloxacin, (E) oxytetracycline and (F) tulathromycin in adult bovine serum against <i>Mmm</i>SC strain B237.</p

Effect of inoculum size on MIC.

<p>Ratio of MIC at different inoculum sizes to MIC at 10⁷ cfu/mL for oxytetracycline (OTC), danofloxacin (DANO) and tulathromycin (TUL) against <i>Mmm</i>SC strain B237 in artificial medium.</p

Supplementary Material for: Thrombolysis for acute wake-up and unclear onset strokes with alteplase at 0.6 mg/kg in clinical practice: THAWS2 Study

Introduction: The aim of this study was to determine the safety and efficacy of intravenous (IV) alteplase at 0.6 mg/kg for patients with acute wake-up or unclear onset strokes in clinical practice. Methods: This multicenter observational study enrolled acute ischemic stroke patients with last-known-well time >4.5 h who had mismatch between DWI and FLAIR and were treated with IV alteplase. The safety outcomes were symptomatic intracranial hemorrhage (sICH) after thrombolysis, all-cause deaths and all adverse events. The efficacy outcomes were favorable outcome defined as an mRS score of 0–1 or recovery to the same mRS score as the premorbid score, complete independence defined as an mRS score of 0–1 at 90 days, and change in NIHSS at 24 h from baseline. Results: Sixty-six patients (35 females; mean age, 74±11 years; premorbid complete independence, 54 [82%]; median NIHSS on admission, 11) were enrolled at 15 hospitals. Two patients (3%) had sICH. Median NIHSS changed from 11 (IQR, 6.75–16.25) at baseline to 5 (3–12.25) at 24 h after alteplase initiation (change, –4.8±8.1). At discharge, 31 patients (47%) had favorable outcome and 29 (44%) had complete independence. None died within 90 days. Twenty-three (35%) also underwent mechanical thrombectomy (no sICH, NIHSS change of –8.5±7.3), of whom 11 (48%) were completely independent at discharge. Conclusions: In real-world clinical practice, IV alteplase for unclear onset stroke patients with DWI-FLAIR mismatch provided safe and efficacious outcomes comparable to those in previous trials. Additional mechanical thrombectomy was performed safely in them